Terms: = Germ cell tumor AND ALK, CD246, ENSG00000171094, 238, Q9UM73, TFG/ALK AND Treatment
292 results:
1. Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to alk inhibitors in alk-mutant neuroblastoma.
Pucci P; Lee LC; Han M; Matthews JD; Jahangiri L; Schlederer M; Manners E; Sorby-Adams A; Kaggie J; Trigg RM; Steel C; Hare L; James ER; Prokoph N; Ducray SP; Merkel O; Rifatbegovic F; Luo J; Taschner-Mandl S; Kenner L; Burke GAA; Turner SD
Nat Commun; 2024 Apr; 15(1):3422. PubMed ID: 38653965
[TBL] [Abstract] [Full Text] [Related]
2. An Infant-Type Hemispheric Glioma With SOX5::alk: A Novel Fusion.
Tsai CC; Huang MH; Fang CL; Hsieh KL; Hsieh TH; Ho WL; Chang H; Tsai ML; Kao YC; Miser JS; Wong TT; Su MY; Liu YL
J Natl Compr Canc Netw; 2024 Feb; 22(1):. PubMed ID: 38394779
[TBL] [Abstract] [Full Text] [Related]
3. Evaluation of Immunohistochemical Expression of alk-1 in Gliomas, WHO Grade 4 and Its Correlation with IDH1-R132H Mutation Status.
Khairy RA; Momtaz EM; Abd El Aziz AM; Shibel PEE
Asian Pac J Cancer Prev; 2024 Jan; 25(1):317-323. PubMed ID: 38285799
[TBL] [Abstract] [Full Text] [Related]
4. Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy.
Wienke J; Visser LL; Kholosy WM; Keller KM; Barisa M; Poon E; Munnings-Tomes S; Himsworth C; Calton E; Rodriguez A; Bernardi R; van den Ham F; van Hooff SR; Matser YAH; Tas ML; Langenberg KPS; Lijnzaad P; Borst AL; Zappa E; Bergsma FJ; Strijker JGM; Verhoeven BM; Mei S; Kramdi A; Restuadi R; Sanchez-Bernabeu A; Cornel AM; Holstege FCP; Gray JC; Tytgat GAM; Scheijde-Vermeulen MA; Wijnen MHWA; Dierselhuis MP; Straathof K; Behjati S; Wu W; Heck AJR; Koster J; Nierkens S; Janoueix-Lerosey I; de Krijger RR; Baryawno N; Chesler L; Anderson J; Caron HN; Margaritis T; van Noesel MM; Molenaar JJ
Cancer Cell; 2024 Feb; 42(2):283-300.e8. PubMed ID: 38181797
[TBL] [Abstract] [Full Text] [Related]
5. alk signaling primes the DNA damage response sensitizing alk-driven neuroblastoma to therapeutic ATR inhibition.
Borenäs M; Umapathy G; Lind DE; Lai WY; Guan J; Johansson J; Jennische E; Schmidt A; Kurhe Y; Gabre JL; Aniszewska A; Strömberg A; Bemark M; Hall MN; Eynden JVD; Hallberg B; Palmer RH
Proc Natl Acad Sci U S A; 2024 Jan; 121(1):e2315242121. PubMed ID: 38154064
[TBL] [Abstract] [Full Text] [Related]
6. Patterns of treatment Failure After Selective Rearranged During Transfection (RET) Inhibitors in Patients With Metastatic Medullary Thyroid Carcinoma.
Hadoux J; Al Ghuzlan A; Lamartina L; Bani MA; Moog S; Attard M; Scoazec JY; Hartl D; Aldea M; Friboulet L; Jules-Clement G; Italiano A; Besse B; Lacroix L; Baudin E
JCO Precis Oncol; 2023 Sep; 7():e2300053. PubMed ID: 38127829
[TBL] [Abstract] [Full Text] [Related]
7. SHP2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of alk Inhibitors in Neuroblastoma.
Valencia-Sama I; Kee L; Christopher G; Ohh M; Layeghifard M; Shlien A; Hayes MN; Irwin MS
Cancer Res Commun; 2023 Dec; 3(12):2608-2622. PubMed ID: 38032104
[TBL] [Abstract] [Full Text] [Related]
8. Identification of
Aktaş TÇ; Kızmazoğlu D; Aktaş S; Gökbayrak ÖE; Serinan E; Erol A; Altun Z; Yuan H; Olgun HN
Technol Cancer Res Treat; 2023; 22():15330338231211138. PubMed ID: 37964559
[TBL] [Abstract] [Full Text] [Related]
9. Cyanine Dye Conjugation Enhances Crizotinib Localization to Intracranial tumors, Attenuating NF-κB-Inducing Kinase Activity and Glioma Progression.
Pflug KM; Lee DW; Tripathi A; Bankaitis VA; Burgess K; Sitcheran R
Mol Pharm; 2023 Dec; 20(12):6140-6150. PubMed ID: 37939020
[TBL] [Abstract] [Full Text] [Related]
10. Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study.
Lode HN; Ehlert K; Huber S; Troschke-Meurer S; Siebert N; Zumpe M; Loibner H; Ladenstein R
Br J Cancer; 2023 Nov; 129(11):1780-1786. PubMed ID: 37813959
[TBL] [Abstract] [Full Text] [Related]
11. Combined large cell neuroendocrine carcinoma, lung adenocarcinoma, and squamous cell carcinoma: a case report and review of the literature.
Zhu Z; Liu Y; Xu H; Ning H; Xia Y; Shen L
J Cardiothorac Surg; 2023 Aug; 18(1):254. PubMed ID: 37653509
[TBL] [Abstract] [Full Text] [Related]
12. New Approaches Towards Targeted Therapy for Childhood Neuroblastoma.
Dalianis T; Lukoseviciute M; Holzhauser S; Kostopoulou ON
Anticancer Res; 2023 Sep; 43(9):3829-3839. PubMed ID: 37648295
[TBL] [Abstract] [Full Text] [Related]
13. Study protocol for a multicenter randomised controlled trial on the (cost)effectiveness of biopsy combined with same-session MR-guided LITT versus biopsy alone in patients with primary irresectable glioblastoma (EMITT trial).
Neutel CLG; Viozzi I; Overduin CG; Rijpma A; Grutters JPC; Hannink G; van Eijsden P; Robe PA; Rovers MM; Ter Laan M
BMC Cancer; 2023 Aug; 23(1):788. PubMed ID: 37612610
[TBL] [Abstract] [Full Text] [Related]
14. Anaplastic Lymphoma Kinase Inhibitors for Therapy of Neuroblastoma in Adults.
Stiefel J; Kushner BH; Roberts SS; Iglesias-Cardenas F; Kramer K; Modak S
JCO Precis Oncol; 2023 Aug; 7():e2300138. PubMed ID: 37561984
[TBL] [Abstract] [Full Text] [Related]
15. Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile.
Ascierto PA; Di Giacomo AM; Chiarion Sileni V; Queirolo P; Spagnolo F; De Galitiis F; Cognetti F; Mandalà M; Guidoboni M; Rinaldi G; Depenni R; Consoli F; Troiani T; Guida M; Marconcini R; Ferrucci PF; Strippoli S; Fava P; Merelli B; Simeone E; Di Guardo L; Giannarelli D; Maio M; Quaglino P; Del Vecchio M
Eur J Cancer; 2023 Sep; 191():113246. PubMed ID: 37549531
[TBL] [Abstract] [Full Text] [Related]
16. Circulating tumor DNA: A Promising Biomarker for Predicting Recurrence in Patients with BRAF-Negative Melanoma.
Aoude LG; Brosda S; Ng J; Lonie JM; Belle CJ; Patel K; Koufariotis LT; Wood S; Atkinson V; Smithers BM; Pearson JV; Waddell N; Barbour AP; Bonazzi VF
J Mol Diagn; 2023 Oct; 25(10):771-781. PubMed ID: 37544359
[TBL] [Abstract] [Full Text] [Related]
17. [Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2023 edition)].
;
Zhonghua Zhong Liu Za Zhi; 2023 Jul; 45(7):539-574. PubMed ID: 37460438
[TBL] [Abstract] [Full Text] [Related]
18. [Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2023 edition)].
;
Zhonghua Yi Xue Za Zhi; 2023 Jul; 103(27):2037-2074. PubMed ID: 37455124
[TBL] [Abstract] [Full Text] [Related]
19. Metabolic protein kinase signalling in neuroblastoma.
Smiles WJ; Catalano L; Stefan VE; Weber DD; Kofler B
Mol Metab; 2023 Sep; 75():101771. PubMed ID: 37414143
[TBL] [Abstract] [Full Text] [Related]
20. Safety and efficacy of lorlatinib against alk-driven refractory or relapsed neuroblastoma.
Suk Y; Singh SK
Cell Rep Med; 2023 Jun; 4(6):101071. PubMed ID: 37343514
[TBL] [Abstract] [Full Text] [Related]
[Next]
